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cerium oxide nanoparticles display 
antilipogenic effect in rats with 
non-alcoholic fatty liver disease
Silvia carvajal1, Meritxell perramón1, Denise oró1, eudald casals  2, Guillermo fernández-
Varo1,3, Gregori casals1,4, Marina parra1, Bernardino González de la presa1, Jordi Ribera1, 
Óscar pastor5, Manuel Morales-Ruíz1,4, Víctor puntes6,7,8 & Wladimiro Jiménez1,3
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide, 
ranging from steatosis to non-alcoholic steatohepatitis (NASH). Recently, cerium oxide nanoparticles 
(CeO2NPs) have emerged as a new antioxidant agent with hepatoprotective properties in experimental 
liver disease. The aim of the current investigation was to elucidate whether CeO2NPs display beneficial 
effects in an experimental model of NAFLD.Therefore, fifteen Wistar rats were subjected to a 
methionine and choline deficient diet (MCDD) for 6 weeks and intravenously treated with CeO2np 
or vehicle during the weeks three and four of the diet. The effect of CeO2NPs on serum biochemistry, 
hepatic steatosis, inflammation, fatty acid content and expression of reactive oxygen species (ROS) and 
lipid metabolism related genes was assessed. MCDD fed rats showed increased inflammation, enhanced 
hepatic lipid accumulation of both saturated and unsaturated fatty acids (FAs) and overexpression of 
genes related to fatty liver and ROS metabolism. Treatment with CeO2NPs was able to reduce the size 
and content of hepatocyte lipid droplets, the hepatic concentration of triglyceride- and cholesterol 
ester-derived FAs and the expression of several genes involved in cytokine, adipokine and chemokine 
signaling pathways. These findings suggest that CeO2NPs could be of beneficial value in NAFLD.
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the world with a 
prevalence of 20–40% in the general population and up to 95% in subjects with obesity and diabetes1,2. NAFLD 
is characterized by an abnormal accumulation of fatty acids inside the hepatocytes and includes a broad spec-
trum of liver diseases, ranging from mild to severe steatosis and non-alcoholic steatohepatitis (NASH)3. In turn, 
hepatocellular lipid accumulation along with liver inflammation, oxidative stress and apoptosis are the main 
characteristics of NASH4,5. Both NAFLD and NASH have the potential to evolve into liver fibrosis and cirrhosis. 
In addition, these diseases increase the risk of developing hepatocellular carcinoma (HCC), which can be related 
to cirrhosis or arise in the steatotic liver without evidence of underlying cirrhosis3,6.
Oxidative stress is considered a key pathogenic mechanism involved in the progression from steatosis to 
NASH7–9. In humans and experimental animal models of NASH, lipotoxicity plays an essential role in cell death 
and in the generation of oxidative stress-related products10,11. Lipid accumulation along with high levels of circu-
lating free fatty acids induce mitochondria structural and functional abnormalities, leading to increased reactive 
oxygen species (ROS) production and apoptosis12. Also, elevated expression and activity of hepatic CYP2E1 has 
been observed in human and animal models of NASH, representing a potent source of ROS13. Moreover, lisoso-
mal permeabilization induced by FFA exposure plays an important role in apoptosis and endoplasmic reticulum 
(ER) stress14. The high levels of ROS further induce oxidative stress with the subsequent activation of inflamma-
tory and profibrogenic pathways15,16. Despite cellular metabolism is dominated by redox-based processes, target-
ing of the cellular redox sensitive pathways—redoxome—is still an uncommon therapeutic practice17. During 
the last few years antioxidant substances, such as superoxide dismutase (SOD), resveratrol, colchicine, eugenol 
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or vitamins E and C raised increasing interest as potential therapeutic agents in chronic liver diseases18–20. These 
substances have demonstrated their efficacy in reequilibrating hepatic ROS metabolism and thereby improving 
liver functionality19,20. However, despite much enthusiasm in the 1980s and 1990s, many well-known agents have 
not successfully passed the scrutiny of clinical trials for prevention and treatment of various diseases21 mainly 
due to unspecificity, and consequent uncontrolled side effects since a minimal level of ROS is needed for normal 
functioning.
Recently, cerium oxide nanoparticles (CeO2NPs) have emerged as a new powerful antioxidant agent with 
therapeutic properties in experimental liver disease. CeO2NPs have been reported to act as a ROS and NOS scav-
engers22 and to have multi-enzyme mimetic activity, including SOD activity23 (disproportionation of superoxide 
anion into oxygen and hydrogen peroxide), catalase activity24 (conversion of hydrogen peroxide into oxygen and 
water) and peroxidase activity25 (reducing hydrogen peroxide into hydroxil radicals). Consequently, the ben-
eficial effects of CeO2NPs treatment have been reported in many different medical fields such as neurology26, 
ophthalmology27, cardiology28, oncology29 and hepatology30, among others. Unlike other antioxidants, CeO2NPs 
are only active at pathogenic levels of ROS, being inert and innocuous in healthy cells31. In this regard, previous 
investigations indicated that CeO2NPs are able to reduce steatosis30, attenuate oxidative stress32–34 and display 
anti-inflammatory properties30,35,36 in different experimental models of liver disease. Hence, we hypothesize that 
CeO2NPs could also have the potential to reduce steatosis, oxidative stress and inflammation in experimental 
MCDD-induced NAFLD. MCDD is widely used and one of the best characterized animal models to study NASH. 
Although it does not resemble the metabolic profile and etiology of human NAFLD, it mimics several of the his-
topathological features of human NAFLD37,38.
In the current study we explored the impact of CeO2NPs on steatosis by assessing the liver histology and 
fatty acid content, macrophage infiltration and the expression of genes involved in inflammation, ROS and lipid 
metabolism in the MCDD experimental model of NAFLD in rats. The aim of the investigation was to elucidate 
whether CeO2NPs reduce the accumulation of fat in the liver, oxidative stress, hepatic content of fatty acids and 
activation of proinflammatory genes in rats with MCDD-induced NAFLD.
Results
Characterization of CeO2NPs. Details regarding the characterization of the CeO2NPs used in this article 
have been described in previous studies30,39. Briefly, HR-TEM analysis at high magnification suggested that the 
nanoparticles had a spherical morphology and were ~4 nm in diameter (Fig. 1). HR-TEM at low magnification 
revealed loose CeO2NPs agglomerates, and the X-ray diffraction pattern of CeO2NPs showed pure nanoparticles 
with the typical peak broadening characteristic of nanosize particles (data not shown).
Body weight, liver to body weight ratio and serum biochemical parameters in control and 
MCDD rats treated with vehicle or CeO2NPs. In parallel to results previously obtained by other 
groups38,40, MCDD animals showed significantly decreased body weight and increased liver to body weight ratio 
than control rats (Table 1). Moreover, they also showed a remarkable alteration in plasma biomarkers of liver 
function. As shown in Table 1, rats fed with the MCDD displayed increased activity of transaminases, hypo-
cholesterolemia, hyperbilirubinemia and significantly decreased levels of circulatory triglycerides. However, we 
were unable to detect any significant difference between rats treated and non-treated with CeO2NPs in any of the 
parameters assessed.
Histological examination of steatosis, inflammation and fibrosis in liver tissue. Figure 2A illus-
trates representative images of H&E, CD68 and Sirius red staining in liver biopsies of control and MCDD rats 
receiving vehicle or CeO2NPs. Macrovesicular steatosis was observed in both groups of MCDD rats as single large 
fat intra cytoplasmatic droplets displacing the nucleus. This alteration, consistent with a well-defined histological 
pattern of NAFLD, was significantly less pronounced in MCDD rats receiving CeO2NPs. Actually, the morpho-
metric measurement of fat revealed a significant decrease of both, lipid content (48,91 ± 3,61 vs. 42,67 ± 5,75; 
%p < 0.001) and fat size (69 ± 6 µm2 vs. 63 ± 9 µm2, p < 0.001) (data not shown) in rats receiving CeO2NPs com-
pared to those receiving vehicle (Fig. 2B). In addition, the MCDD also resulted in a significant inflammatory 
Figure 1. Characterization of the 4 nm CeO2NPs: (A) TEM image revealing CeO2NPs (scale bar is 100 nm) and 
(B) typical UV-VIS spectrum of the CeO2NPs after purification and resuspension in TMAOH 1 mM.
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cell infiltrate in the liver tissue. However, quantification of CD68-positive stained cells did not show statistical 
differences between MCDD rats treated or non-treated with CeO2NPs (Fig. 2C). Finally, MCDD rats showed 
mild perivenular and portal fibrosis, with no significant differences between rats receiving and non-receiving 
CeO2NPs.
Hepatic lipid peroxidation. In order to evaluate the oxidative stress-induced damage in the MCDD model 
of NAFLD and the antioxidant effects of CeO2NPs, lipid peroxidation was assessed by measuring malondialde-
hyde (MDA) content in the liver. A marked increment in the hepatic levels of MDA was found in MCDD rats 
treated with vehicle as compared to control rats. The level of MDA in the liver of the MCDD rats treated with 
CeO2NPs was significant lower than in those animals receiving vehicle (Fig. 3).
Control (n = 5)
MCDD rats
Vehicle (n = 8) CeO2NPs (n = 7)
Body weight (g) 425.6 ± 6.7 275.3 ± 4.8*** 274.5 ± 3.4***
Liver/body weight (%) 2.9 ± 0.18 4.1 ± 0.17** 4.2 ± 0.17***
Alanine transaminase (U/L) 35.3 ± 3.1 179.1 ± 26.6** 199.8 ± 24.2***
Aspartate transaminase (U/L) 49.1 ± 6.4 143.8 ± 14.52* 149.1 ± 15.1**
Gamma Glutamyl Transpeptidase (U/L) 2.1 ± 0.02 3.2 ± 0.5 2.8 ± 0.15
Total cholesterol (mg/dL) 69.4 ± 4.9 25.8 ± 1.7*** 28.4 ± 2***
Total bilirubin (mg/dL) 0.00 ± 0.08 0.29 ± 0.06* 0.24 ± 0.05
Triglycerides (mg/dL) 192.2 ± 14.8 20.2 ± 1.4*** 22.7 ± 2.1***
Glucose (mg/dL) 145.1 ± 6.9 120.2 ± 6.9 126.6 ± 4.6
Total proteins (g/L) 65.8 ± 1.2 63.3 ± 1.4 63.1 ± 1.2
Albumin (g/L) 34.9 ± 0.5 37.1 ± 0.7 37.2 ± 0.64
Table 1. Body weight, liver body weight ratio, and serum biochemical parameters test results in control and 
MCDD rats treated with vehicle or CeO2NPs. *p < 0.05,**p < 0.01, ***p < 0.001 compared to control group. 
One-way ANOVA with Newman-Keuls post hoc test and Kruskal-Wallis with Dunn’s test post hoc when 
appropriate. Results are shown as mean ± SEM.
Figure 2. Effect of CeO2NPs on hepatic histology. (A) Hematoxylin & Eosin, CD68 and Sirius Red staining 
of representative liver sections obtained from control rats, MCDD rats receiving vehicle and MCDD rats 
receiving CeO2NPs. Original magnification 100x for H&E and Sirius Red, and 200x for CD68. (B) Quantitative 
measurement of fat content (%) in MCDD animals. ***p < 0.001 compared to vehicle group. Unpaired 
Student’s t test. (C) Quantitative measurement of CD68 positive cells/field in all animals. ***p < 0.01 compared 
to control group. One way ANOVA with Turkey’s multiple comparison test. Results are shown as mean ± SEM.
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Hepatic lipid profiling. Further information on the metabolic alterations associated with the diet-induced 
experimental NALFD model was obtained by measuring the principal lipid components in the liver of control 
and MCDD rats. As shown in Table 2, total FAs in TG, CE, PC and PE showed marked differences between con-
trol and MCDD rats. As anticipated, the liver content of total TG- and CE-derived FAs was markedly increased 
in MCDD rats in comparison to control animals. However, these differences were not seen on analyzing PC- and 
PE-derived FAs. On the contrary, in these cases we observed significantly reduced content of total FAs in the 
liver of MCDD animals. This can be explained by the lack of methionine and choline in the diet of the MCDD 
group. The effect induced by CeO2NPs administration on PC- and PE-derived FAs are shown in Tables 3 and 4 
respectively.
Marked abnormalities were found in both chromatographic patterns of TG- and CE-derived FAs of MCDD 
rats (Fig. 4). As compared to control animals, the most remarkable differences were, in TG-derived FAs, the pres-
ence of high or very high hepatic content of C16:0, C17:0, C18:0, C18:1n9, C18:2n6, C18:3n6, C18:3n3, C20:0, 
C20:1n9, C20:2, C20:3n6, C20:4n6, C20:5n3, C22:1n9 and C22:6n3 FAs (Table 5). This was due to a significantly 
increase of both saturated (SFA) and unsaturated (UFA) FAs. Furthermore, in the latter case this augmentation 
was a consequence of higher levels of both mono (MUFA) and poly UFA (PUFA). Moreover, the peroxidisability 
index (PI), an indicator of PUFA peroxidation41–43 that represents the degree of unsaturation of dietary lipids, was 
significantly higher in MCDD rats than in control animals (0.95 ± 0.05 vs 0.61 ± 0.06 nmol/mg tissue, p < 0.01). 
The pattern was quite similar in CE-derived FAs being C14:0, C15:0, C16:0, C16:1, C18:0, C18:1n9, C18:2n6, 
C18:3n6, C18:3n3, C20:0, C20:1n9, C20:2, C20:3n6, C20:4n6, C22:0 and C22:6n3 the FAs increased in this case. 
SFA and UFA were also found significantly increased in MCDD in comparison to control rats (Table 6). The PI 
was higher too, although did not reach statistical significance (1.08 ± 0.14 vs 0.67 ± 0.01 nmol/mg tissue).
Administration of CeO2NPs markedly altered the lipogenic activity in MCDD animals as indicated by a 26% 
and 33% decrease in the liver content of total TG and CE, respectively. A significant decrease in TG-derived 
MUFA, almost exclusively due to a diminution in TG-derived oleic acid, was observed (Fig. 5A). The most 
remarkable effects, however, were noted on analyzing CE-derived FAs. CeO2NPs treatment decreased SFA, MUFA 
and PUFA by approximately 50.7%, 38.7% and 25.6%, respectively (Fig. 5B). In the former case, this diminution 
was due to a lesser abundance of myristic, pentadecylic and palmitic acids, whereas palmitoleic and oleic acids 
and linolelaidic and γ-linolenic acids were the principal contributors in MUFA and PUFA, respectively. CeO2NPs 
did not significantly modify the altered PI in MCDD rats. Interestingly, we also observed that CeO2NPs induced a 
significant increase in the CE-derived very long chain PUFA, C22:6n3 (docosahexaenoic acid) (Table 6).
Figure 3. Levels of malondialdehyde (MDA) in MCDD fed rats. Content of MDA in the liver of control and 
MCDD non-treated (VH) and treated (CeO2NPs) rats (nmol/mg tissue). **p < 0.01 vs. control rats; †p < 0.05 vs. 
MCDD rats receiving. VH Unpaired Student’s t-test. Results are given as means ± SEM.
Control (n = 5) MCDD (n = 8)
Triglycerides 199.8 ± 84.3 1348.9 ± 167.3***
Cholesterol Esters 6.7 ± 1.27 73.2 ± 9.4***
Phosphatidylcholines 1647.3 ± 90.4 825.8 ± 38.8***
Phosphatidylethanolamines 78.7 ± 7.3 60.8 ± 4.2*
Table 2. Total FA of principal lipid components in the hepatic tissue of control and MCDD rats (nmol/mg 
tissue). Values are expressed as mean ± SEM. ***p < 0.001 and *p < 0.05, vs. control rats. Unpaired Student’s 
t-test.
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Effect of CeO2NPs on fatty liver metabolism related gene expression in liver tissue. Further 
insight on the effect of CeO2NPs in the liver of MCDD rats was obtained by assessing messenger expression of 86 
genes involved in fatty liver metabolism using a commercially available PCR array. Table 7 depicts all the genes 
showing a 2-fold or greater change in expression between the liver of MCDD rats receiving vehicle and that of 
control rats. Nine genes were significantly upregulated, including Cd36, a gene encoding for an enzyme involved 
in the adipokine signaling pathway, genes related to metabolic pathways (Abcg1, Apoa1, Ctp1a, Gk and Lpl), the 
Il1β gene, related to inflammatory response, and apoptosis-related genes (Fas and Serpine1). By contrast, four 
genes were significantly down-regulated, including those encoding insulin signaling pathway enzymes (Igf1 and 
Pklr) or controlling other metabolic pathways (Scd1 and Slc27a5).
A 2-fold or greater change in expression with p < 0.05 was considered statistically significant on compar-
ing rats treated with vehicle vs. the CeO2NPs treated MCDD rats. Volcano plots of the data are presented in 
Fig. 6. Interestingly, CeO2NPs exerted a significant inhibitory effect on the expression of two genes related to the 
Fatty acid Control (n = 4)
MCDD rats
Vehicle (n = 8) CeO2NPs (n = 7)
C4:0 ND ND ND
C6:0 ND ND ND
C8:0 ND ND ND
C10:0 0.74 ± 0.14 1.46 ± 0.40 0.98 ± 0.19
C11:0 ND ND ND
C12:0 0.95 ± 0.19 1.25 ± 0.28 1.19 ± 0.16
C13:0 0.07 ± 0.01 0.18 ± 0.05 0.12 ± 0.03
C14:0 8.24 ± 0.94 2.84 ± 0.19*** 2.53 ± 0.12**
C14:1 0.29 ± 0.04 0.35 ± 0.05 0.43 ± 0.05
C15:0 4.53 ± 0.14 1.93 ± 0.12*** 1.68 ± 0.09**
C15:1 ND ND ND
C16:0 439.12 ± 39.28 237.78 ± 9.44*** 236.56 ± 10.72**
C16:1 26.80 ± 8.10 3.54 ± 0.35** 3.43 ± 0.20**
C17:0 7.07 ± 0.97 2.74 ± 0.15*** 2.71 ± 0.14**
C17:1 ND ND ND
C18:0 235.17 ± 29.60 147.84 ± 5.70** 149.53 ± 7.06**
C18:1n9 120.75 ± 16.74 54.88 ± 5.42*** 52.05 ± 2.87**
C18:2n6 272.01 ± 23.96 119.42 ± 7.47*** 116.67 ± 4.89**
C18:3n6 3.38 ± 0.50 2.82 ± 0.34 2.72 ± 0.26
C18:3n3 3.76 ± 0.25 3.02 ± 0.38 2.97 ± 0.35
C19:0 IS IS IS
C20:0 1.13 ± 0.04 0.77 ± 0.02*** 0.83 ± 0.04**
C20:1n9 0.79 ± 0.09 0.49 ± 0.052** 0.55 ± 0.05*
C20:2 6.83 ± 0.69 1.55 ± 0.21*** 2.17 ± 0.11**,†
c20:3n3 ND ND ND
C20:3n6 12.61 ± 1.91 6.24 ± 0.44** 6.63 ± 0.51*
C20:4n6 437.89 ± 16.47 201.99 ± 10.54*** 226.46 ± 9.89**
C20:5n3 ND ND ND
C21:0 0.12 ± 0.01 0.11 ± 0.01 0.12 ± 0.01
C22:0 1.84 ± 0.14 1.59 ± 0.08 1.51 ± 0.11
C22:1n9 0.56 ± 0.12 0.63 ± 0.13 0.680 ± 0.13
C22:2 0.38 ± 0.08 0.51 ± 0.07 0.66 ± 0.04*
C22:6n3 51.68 ± 2.731 21.66 ± 2.11*** 23.78 ± 1.62*
C23:0 1.59 ± 0.17 1.10 ± 0.10* 1.10 ± 0.09*
C24:0 6.58 ± 0.81 6.30 ± 0.47 6.41 ± 0.68
C24:1n9 2.49 ± 0.29 2.82 ± 0.28 3.50 ± 0.42
SFA 707.17 ± 54.23 405.88 ± 15.12** 405.26 ± 16.12**
UFA 940.22 ± 40.09 419.92 ± 24.39*** 442.70 ± 17.16**
MUFA 151.67 ± 24.37 62.70 ± 5.65** 60.63 ± 2.84**
PUFA 788.54 ± 38.40 357.22 ± 19.72*** 382.06 ± 14.57**
Table 3. Content of PC-derived FAs in the liver of control and MCDD non-treated (vehicle) and treated 
(CeO2NPs) rats (nmol/mg tissue). Values are expressed as mean ± SEM. SFA, saturated fatty acids; UFA, 
unsaturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; ND, non-
detected peak; IS, internal standard. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control rats; †p < 0.05 vs. MCDD 
rats receiving vehicle. Unpaired Student’s t-test and Mann Whitney test when appropriate.
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adipokine signaling pathway (Cd36 and Lepr); one gene related to the fatty acid oxidation (Cpt1a) and the inflam-
matory response-related genes Il1β, Il10 and Cebpb. A significant reduction in Igf1 expression was also observed, 
but the biological significance of this data was roughly less than 2-fold.
Effect of CeO2NPs on oxidative stress-associated gene expression in liver tissue. The relative 
expression of 86 genes from several pathways involved in oxidative stress and antioxidant defense was assessed in 
the liver of MCDD rats treated with vehicle or CeO2NPs using a commercially available PCR array. Table 8 shows 
all the genes presenting a 2-fold or greater change in expression between the liver of the MCDD vehicle-treated 
group and that of control rats. MCDD induced significant changes in the expression of 31 genes; 27 were upreg-
ulated and 4 down regulated. The up-regulated genes included genes encoding enzymes involved in antioxi-
dant metabolism (Ehd2, Epx, Gpx2, Gpx3, Gpx7, Gstp1, Prdx2, Ptgs1, Ptgs2, Serpinb1b, Srxn1 and Vimp), genes 
related to ROS metabolism (Ccl5, Cyba, Fmo2 Hmox1, Ncf1, Ncf2, Nos2, Prnp and Ucp2), genes encoding oxygen 
transporters (Cygb, Dnm2, Slc38a1 and Vim) and endoplasmic reticulum stress related genes (Atf3 and Ddit3). 
Meanwhile, the four down-regulated genes, encoded the antioxidant enzyme catalase (Cat), genes controlling 
ROS metabolism (Nox4 and Scd1) and one gene involved in oxygen transport (Hba1). A 2-fold or grater change 
Fatty acid Control (n = 4)
MCDD rats
Vehicle (n = 8) CeO2NPs (n = 7)
C10:0 ND ND ND
C11:0 ND ND ND
C12:0 ND ND ND
C13:0 ND ND ND
C14:0 0.09 ± 0.02 0.09 ± 0.03 0.04 ± 0.00*
C14:1 ND ND ND
C15:0 IS IS IS
C15:1 ND ND ND
C16:0 17.57 ± 1.68 13.24 ± 0.95* 12.67 ± 1.07*
C16:1 0.71 ± 0.18 0.22 ± 0.04** 0.21 ± 0.03**
C17:0 0.40 ± 0.06 0.26 ± 0.018* 0.26 ± 0.01*
C17:1 0.10 ± 0.02 0.10 ± 0.01 0.10 ± 0.01
C18:0 11.31 ± 2.29 13.19 ± 1.18 13.31 ± 1.00
C18:1n9 6.37 ± 0.88 4.42 ± 0.47 4.13 ± 0.35*
C18:2n6 8.21 ± 1.07 4.96 ± 0.53* 5.06 ± 0.42**
C18:3n6 0.16 ± 0.031 0.18 ± 0.03 0.17 ± 0.02
C18:3n3 0.38 ± 0.08 0.37 ± 0.09 0.39 ± 0.07
C19:0 ND ND ND
C20:0 0.06 ± 0.01 0.07 ± 0.01 0.06 ± 0.01
C20:1n9 ND ND ND
C20:2 0.20 ± 0.03 0.14 ± 0.02 0.16 ± 0.02
C20:3n3 ND ND ND
C20:3n6 0.69 ± 0.11 0.57 ± 0.04 0.61 ± 0.04
C20:4n6 27.55 ± 2.31 15.75 ± 1.11*** 16.28 ± 1.00***
C20:5n3 ND ND ND
C21:0 ND ND ND
C22:0 0.05 ± 0.01 0.04 ± 0.01 0.05 ± 0.00
C22:1n9 ND ND ND
C22:2 ND ND ND
C22:6n3 4.81 ± 0.67 12.09 ± 1.25 7.10 ± 0.97***,††
C23:0 ND ND ND
C24:0 ND ND ND
C24:1n9 0.083 ± 0.026 0.081 ± 0.032 0.12 ± 0.02
SFA 29.48 ± 3.94 26.89 ± 2.16 26.39 ± 2.07
UFA 49.27 ± 3.48 33.89 ± 2.28** 39.32 ± 2.16*
MUFA 72.65 ± 1.01 4.82 ± 0.53* 4.55 ± 0.36*
PUFA 42.00 ± 3.31 29.07 ± 2.09** 34.76 ± 1.86
Table 4. Content of PE-derived FAs in the liver of control and MCDD non-treated (vehicle) and treated 
(CeO2NPs) rats (nmol/mg tissue). Values are expressed as mean ± SEM. SFA, saturated fatty acids; UFA, 
unsaturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids. ND, non-
detected peak; IS, internal standard. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control rats; ††p < 0.01 vs. MCDD 
rats receiving vehicle. Unpaired Student’s t-test and Mann Whitney test when appropriate.
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in expression with p < 0.05 was considered statistically significant on comparing rats treated with vehicle vs. the 
CeO2NPs treated MCDD rats. Volcano plots of the data are presented in Fig. 7. CeO2NPs exerted a significant 
inhibitory effect on the expression of six genes related to antioxidant metabolism (Epx, Gpx7, Gstp1, Prdx2, Prdx4 
and Vimp) and four genes related to ROS metabolism (Aox1, Ccl5, Hmox1 and Ncf1). However, an inhibitory 
effect greater than two fold was only observed on analyzing gene expression of Epx, Prdx4 and Ccl5. To verify the 
results obtained by PCR array, we used quantitative RT-PCR to assess the expression level of most genes showing 
differential expression in the presence of CeO2NPs. The quantitative gene expression analysis demonstrated paral-
leled the results previously found in the array profiler. In fact, administration of CeO2NPs significantly decreased 
mRNA abundance of all the assessed genes (Fig. 8).
Discussion
In the current study we explored the effects of CeO2NPs on hepatic steatosis, inflammatory response, oxidative 
stress and liver fatty acid content in a MCDD-induced animal model of NAFLD. MCDD is among the most 
commonly used experimental methods to quickly induce liver steatosis and other hallmarks of NAFLD44. This 
diet, with high sucrose and 10% fat, but deficient in methionine and choline, results in macrovesicular steatosis 
within 3–4 weeks, progressing to inflammation and fibrosis45. As in previous investigations38, MCDD rats in the 
present study showed malnutrition, weight loss and a proportional increase in liver weight. Liver injury induced 
by MCDD was also associated with reduced serum levels of triglycerides and cholesterol, likely due to hepatic 
blockade of VLDL synthesis. Three weeks after starting the administration of the MCDD, when NAFLD was fully 
established but without reaching the most severe type of NASH, the iv administration of CeO2NPs was initiated. 
No noticeable effects on serum biochemistry parameters were observed following two weeks of CeO2NPs treat-
ment. However, nanoparticles were able to reduce the hepatic fat content and the lipid droplet size in diet induced 
NAFLD animals. These apparently contradictory results at first may be explained by the fact that probably after 
Figure 4. Liver fatty acid composition in control and MCDD rats. Superposition of representative gas 
chromatography mass spectrometry (GC/MS) chromatograms obtained from analysis of the TG- and CE-
derived FAs of control (green) and non-treated (orange) and treated (blue) MCDD rats. GC peaks are labeled 
with the corresponding FA identification.
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6 weeks of MCDD administration NAFLD intensity is already very high, and the significant steatosis reduction 
induced by CeO2NPs is not sufficient to represent a change in the analyzed serum parameters.
It is well known that feeding rats with MCDD increases lipid peroxidation and oxidative stress, which results 
in hepatocellular damage45,46. Actually, in the current investigation we observed a significant increment of 
MDA concentration in the liver of the MCDD rats, confirming thus the lipid peroxidation in these animals. 
Interestingly, CeO2NPs were able to reduce MDA concentration, indicating a marked reduction in the intensity 
of the lipid peroxidation. Moreover, this diet also results in remarkably increased hepatic FA accumulation47. 
Thus, we next sought to precisely assess whether CeO2NPs modify the FA pattern in animals with NAFLD. As 
expected, a dramatic difference in liver FA composition was observed between MCDD and control rats. MCDD 
animals showed between 2 to 30-fold higher FA content in hepatic TG and CE. Interestingly, regardless of which 
principal lipid component they were derived, the majority of these FAs were MUFA and PUFA. Interestingly, a 
marked reduction in SFAs and UFAs was observed in our MCDD animals treated with CeO2NPs. In view of the 
alterations induced by CeO2NPs, the goal of the next part of the study was to investigate the changes in expression 
of genes involved in hepatic lipid and ROS metabolism as a result of the MCDD, and to compare these changes to 
those obtained following CeO2NPs administration. The fatty liver and oxidative stress RT2 Profiler™ arrays used 
to determine hepatic gene expression have previously been successfully used in rat liver tissue30,47,48. In the present 
study we identified 14 MCDD-induced genes involved in β-oxidation pathways, adipokine signaling, inflamma-
tion and antioxidant and ROS metabolism that were significantly down-regulated or even normalized following 
Fatty acid
Control rats 
(n = 4)
MCDD rats
Vehicle (n = 8) CeO2 NPs (n = 7)
C10:0 1.12 ± 0.71 0.52 ± 0.20 0.33 ± 0.09
C12:0 1.22 ± 0.64 0.48 ± 0.13 0.34 ± 0.07
C13:0 0.24 ± 0.1 0.04 ± 0.01 0.02 ± 0.0
C14:0 3.55 ± 1.99 5.32 ± 1.13 4.48 ± 0.57
C14:1 0.63 ± 0.36 0.20 ± 0.12 0.08 ± 0.02
C15:0 0.77 ± 0.36 1.94 ± 0.39 1.43 ± 0.16
C16:0 58.2 ± 24.5 303.4 ± 38.7*** 220.5 ± 20.1***
C16:1 14.5 ± 9.4 8.3 ± 1.9 6.5 ± 0.8
C17:0 0.27 ± 0.12 1.73 ± 0.37* 1.35 ± 0.18 **
C17:1 0.46 ± 0.22 0.61 ± 0.17 0.43 ± 0.05
C18:0 3.08 ± 1.28 42.0 ± 5.9*** 34.6 ± 4.1***
C18:1n9 44.3 ± 19.5 237.6 ± 28.6*** 161.0 ± 17.8**,†
C18:2n6 54.8 ± 20.1 516.1 ± 66.6*** 384.1 ± 47.2***
C18:3n6 1.2 ± 0.4 21.5 ± 4.3** 19.7 ± 2.5***
C18:3n3 4.0 ± 1.7 19.7 ± 3.1** 14.3 ± 2.**
C19:0 IS IS IS
C20:0 0.21 ± 0.11 0.61 ± 0.12* 0.43 ± 0.04
C20:1n9 0.51 ± 0.24 2.47 ± 0.53* 1.77 ± 0.19**
C20:2 0.34 ± 0.20 7.27 ± 1.66** 5.3 ± 0.65***
C20:3n6 1.28 ± 0.53 19.87 ± 4.81* 14.57 ± 1.71***
C20:4n6 5.2 ± 2.0 112. ± 18.8** 91.8 ± 9.3***
C20:5n3 1.2 ± 0.5 4.6 ± 0.7*** 4.6 ± 0.6***
C21:0 0.08 ± 0.04 0.04 ± 0.00 0.03 ± 0.00
C22:0 0.19 ± 0.12 0.14 ± 0.02 0.09 ± 0.01
C22:1n9 0.10 ± 0.03 0.28 ± 0.05* 0.19 ± 0.03
C22:2 0.30 ± 0.16 0.49 ± 0.16 0.42 ± 0.07
C22:6n3 1.1 ± 0.5 14.5 ± 3.8* 12.9 ± 2.0**
C23:0 0.07 ± 0.03 0.031 ± 0.00 0.031 ± 0.00
C24:0 0.20 ± 0.15 0.08 ± 0.02 0.132 ± 0.0
C24:1n9 0.18 ± 0.05 0.19 ± 0.06 0.12 ± 0.02
SFA 69.3 ± 30.0 356.4 ± 45.4*** 264.8 ± 24.0***
UFA 130.5 ± 54.3 966.6 ± 128.0*** 718.0 ± 80.7***
MUFA 60.7 ± 29.6 249.8 ± 30.1** 170.1 ± 17.9**,†
PUFA 69.7 ± 25.2 716.8 ± 99.6*** 547.9 ± 63.9***
Table 5. Content of Triglyceride-derived FAs in the liver of control, non-treated (vehicle) and treated (CeO2 
NPs) MCDD rats (nmol/mg tissue). Values are expressed as mean ± SEM. SFA, saturated fatty acids; UFA, 
unsaturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids. ND, non-
detected peak; IS, internal standard. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control rats; †p < 0.05 vs. MCDD 
rats receiving vehicle. Unpaired Student’s t-test and Mann Whitney test when appropriate.
9Scientific RepoRtS |         (2019) 9:12848  | https://doi.org/10.1038/s41598-019-49262-2
www.nature.com/scientificreportswww.nature.com/scientificreports/
CeO2NPs administration. One additional gene related to antioxidant metabolism that was not induced by the 
MCDD was also markedly down-regulated by the administration of CeO2NPs. Finally, we also identified two 
genes involved in insulin signaling and ROS metabolism that displayed decreased mRNA expression in MCDD 
fed rats, an effect further accentuated when the animals also received CeO2NPs. The molecular function of most 
of these genes, including Gstp1, Hmox1, Igf1, Il1β, Il10, Ccl5, Cebpb, Cd36 and Cpt1a was related to protein 
binding interaction. However, a more stringent analysis of the alterations in gene expression induced by CeO2NPs 
in MCDD fed animals, considering only those genes showing both statistical and biological significance, revealed 
two major groups of genes involved in lipid oxidation and cytokine signaling. The former group comprises Epx, 
Prdx4 and Cpt1a whereas the second group is formed by Il1β, Il10, Ccl5 (RANTES), Cd36, Lepr and Cebpb.
Analysis of the tissue FA profile has become increasingly important in understanding the role of lipids in phys-
iological or pathological processes49,50. FAs are the essential components of lipids. In the recent years, it has been 
suggested that FAs play important roles as intracellular signaling molecules involved for instance in turning on 
nuclear receptors, including the peroxisome proliferator activate receptors (Ppar) which regulate lipid and carbo-
hydrate metabolism transport and cellular proliferation51–53. In addition, it has been reported that a high presence 
of unsaturated FAs could lead to an increased of ROS production and cause mitochondrial permeability leading 
to apoptosis or necrosis54. In this regard, oxidative stress has been proposed as a major mechanism involved in 
NAFLD pathology. The antioxidant N-acetylcysteine has been found to attenuate the progression of NASH55. In 
the present study, the analysis of FAs hepatic composition showed a dramatic increase of FA in MCDD compared 
Fatty acid Control (n = 4)
MCDD rats
Vehicle (n = 8) CeO2NPs (n = 7)
C10:0 ND ND ND
C12:0 ND ND ND
C13:0 ND ND ND
C14:0 24.2 ± 6.0 250.3 ± 64.1* 60.8 ± 9.8*,†
C14:1 30.5 ± 6.7 38.4 ± 6.9 73.8 ± 12.9 *,†
C15:0 11.7 ± 6.6 117.5 ± 20.8** 52.5 ± 7.7**,†
C16:0 3634.4 ± 630.0 16464.0 ± 2863.0* 8204.5 ± 621.0**,†
C16:1 98.6 ± 69.5 625.7 ± 43.8*** 503.1 ± 30.7***,†
C17:0 IS IS IS
C17:1 62.7 ± 16.1 64.4 ± 8. 96.371 ± 18.0
C18:0 347.8 ± 59.5 2503.4 ± 535.0* 1342.0 ± 169.0**
C18:1n9 711.9 ± 158.0 14427.7 ± 2298.0** 8602.7 ± 692.0***,†
C18:2n6 834.2 ± 151.0 26354.5 ± 3951.0** 16129.1 ± 1306.0***,†*,†
C18:3n6 43.1 ± 21.1 698.9 ± 153.0* 292.116 ± 17.2**,†
C18:3n3 77.5 ± 16.5 1127.9 ± 159.0** 828.6 ± 64.1***
C19:0 ND ND ND
C20:0 7.8 ± 2.4 59.8 ± 14.1* 38.0 ± 8.9*
C20:1n9 16.8 ± 7.6 159.6 ± 50* 46. ± 10.2*
C20:2 17.6 ± 6.5 277.6 ± 93.8** 87.4 ± 25.9**
C20:3n6 44.8 ± 12.5 653.4 ± 143.0* 411.600 ± 60.8**
C20:4n6 635.9 ± 114.0 8533.6 ± 1273.0** 9311.5 ± 831.0***
C20:5n3 ND ND ND
C21:0 5.4 ± 2.1 8.3 ± 0.7 12.6 ± 4.3
C22:0 7.3 ± 2.1 24.2 ± 3.3** 24.9 ± 5.2*
C22:1n9 49.2 ± 8.6 112.6 ± 27.1 133.6 ± 18.6*
C22:2 33.2 ± 11.7 69.3 ± 13.7 83.114 ± 17.6
C22:6n3 73.1 ± 21.4 557.8 ± 46.0*** 997.4 ± 75.1***,†††
C23:0 5.3 ± 1.8 6.6 ± 1.1 9.4 ± 2.4
C24:0 9.1 ± 3.4 31.2 ± 5.3* 35.6 ± 7.1*
C24:1n9 ND ND ND
SFA 3966.4 ± 740.0 19465.8 ± 3471.0* 9780.7 ± 756.3***,†
UFA 2705.1 ± 520.1 53701.3 ± 6375.0*** 37597.2 ± 2530.0***,†
MUFA 945.2 ± 228.5 15428.0 ± 2346.0** 9456.1 ± 697.8***,†
PUFA 1759.8 ± 323.2 38273.3 ± 4237.0*** 28141.1 ± 2140.0***
Table 6. Content of CE-derived FAs in the liver of control and MCDD non-treated (vehicle) and treated 
(CeO2NPs) rats (pmol/mg tissue). Values are expressed as mean ± SEM. SFA, saturated fatty acids; UFA, 
unsaturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids. ND, non-
detected peak; IS, internal standard. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control rats; †p < 0.05, †††p < 0.001 
vs. MCDD rats receiving vehicle. Unpaired Student’s t-test and Mann Whitney test when appropriate.
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to control rats. Interestingly, the majority of these FAs were UFA (both MUFA and PUFA), which are more vul-
nerable to oxidation by free radicals and are pointed as a major source of lipid peroxidation56. Lipid peroxidation 
is a mechanism involved in the development and progression of NASH57,58 triggered specifically by the presence 
of ROS59. Oxidizing agents such as ROS can attack double bonded FAs, especially PUFAs, producing lipids with 
peroxide and hydroxyperoxide radicals56. Lipid peroxides can have lipotoxic effects on mitochondrial DNA, RNA 
Figure 5. Effect of CeO2NPs on liver fatty acid composition in MCDD fed rats. (A) TG-derived FAs in the liver 
of control (CT) and MCDD non-treated (VH) and treated (CeO2NPs) rats (nmol/mg tissue). (B) Content of 
CE-derived FAs in the liver of CT and MCDD non-treated and treated rats (pmol/mg tissue). SFA, saturated 
fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids. *p < 0.05, **p < 0.01, 
***p < 0.001 vs. control rats; †p < 0.05 vs. MCDD rats receiving VH Unpaired Student’s t-test. Results are given 
as means ± SEM.
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Genes
MCDD rats
Vehicle (n = 5) CeO2NPs (n = 4)
Insulin Signaling Pathway:
Igf1 −2.14* −4.27*,†
Igfbp1 43.05 16.71
Pklr −3.51** −4.23**
Ppargc1a 8.13 4.97**
Slc2a4 −4.88 −7.75*
Socs3 2.59 1.26
Srebf1 −1.75 −3.27*
Adipokine Signaling Pathway:
Adipor1 2.09 1.05
Cd36 7.25** 3.23***,†
Lepr 2.76 −1.02†
Slc2a1 2.69 1.19
Metabolic Pathways:
Acly −2.18 −2.82
Abcg1 5.66* 2.83*
Acaca −2.17 −4.17**
Acadl 2.25 1.59
Acsm3 −1.61 −2.76
Apoa1 2.61* 1.86*
Apoc3 −1.92* −2.83**
Atp5c1 2.14 1.21
Cyp2e1 2.98 1.70
Cyp7a1 2.50 2.18
Cpt1a 3.07* 1.42†
Fabp3 3.35 2.05
Fasn −2.87 −3.46
G6pc −1.24 −2.02
G6pd 3.32 1.90**
Gck 2.09 3.30
Gk 2.33* 1.44
Hmgcr 3.07 1.98
Lpl 16.11* 9.24**
Mlxipl −1.64 −2.34
Nr1h4 −2.18 −2.46*
Pck2 6.25 4.35*
Pdk4 3.01 1.24
Ppard 2.96 1.69
Scd1 −45.15*** −27.08**
Slc27a5 −5.52** −7.02*
Srebf2 2.42 1.23
Inflammatory Response:
Il1B 3.48* 1.10†
Tnf 6.33 2.65
Apoptosis:
Casp3 2.34 1.14
Fas 4.41* 2.29*
Serpine1 13.76* 7.26*
Table 7. Messenger expression of genes involved in the pathogenic mechanisms of fatty liver showing 2-fold 
or greater regulation in liver between controls and MCDD rats treated with vehicle or CeO2NPs. Abcg1, ATP-
binding cassette, subfamily G (WHITE), member 1; Acaca, Acetyl-coenzyme A carboxylase alpha; Acadl, Acyl-
CoA Dehydrogenase, Long Chain; Acly, ATP citrate lyase; Acsm3, Acyl-CoA synthetase medium-chain family 
member 3; Adipor1, Adiponectin receptor 1; ApoA1, apolipoprotein A-1; Apoc3, Apolipoprotein C-III; Atp5c1, 
ATP synthase subunit gamma, mitochondrial; Casp3, Caspase 3; Cd36, Cd36 molecule (thrombospondin 
receptor); Cpt1a, Carnitine palmitoyltransferase 1a, liver; Cyp2e1, Cytochrome P450, family 2, subfamily e, 
polypeptide 1; Cyp7a1, Cytochrome P450, family 7, subfamily a, polypeptide 1; Fabp3, Fatty acid binding 
protein 3, muscle and heart; Fas, Fas (TNF receptor superfamily, member 6); Fasn, Fatty acid synthase; G6pc, 
Glucose-6-phosphatase, catalytic subunit; G6pd, Glucose-6-phosphate dehydrogenase; Gck, Glucokinase; 
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and mitochondrial machinery proteins, thus contributing to mitochondrial dysfunction60. Among the secondary 
products of lipid peroxidation are MDA and 4-hydroxinonenal (HNE)61 that contributes to liver fibrosis and 
inflammation62,63. In this study we observed a marked increment of lipid peroxidation in the liver of the MCDD 
rats, and, furthermore, we demostrated that CeO2NPs have the potential to significantly reduce this process, thus, 
attenuating the associated lipotoxic effects. N-acetyl cysteine (NAC) is a widely used antioxidant, often used to 
protect the liver from oxidative damage caused by ROS. Due to the short half-life of NAC, it is useful to treat 
acute oxidative stress, however, it is not practical for the treatment of chronic oxidative stress64,65. On the other 
side, CeO2NPs remain deposited in the liver for a period of at least 30 days66. This property, together with their 
regenerative nature, would make the use of nanoceria a more interesting antioxidant approach against chronic 
oxidative stress66. Previous studies have compared the biological effects exerted by CeO2NPs with that exerted 
by NAC, demonstrating that CeO2NPs have similar antioxidant effects compared to NAC, but a longer half-life. 
Specifically, CeO2NPs showed a trend for greater inhibition of lipoperoxidation and ROS production compared 
to the NAC-treated animals in mice with liver damage66, a similar ability to increase GSH compared to NAC in 
cells under H2O2-induced oxidative stress67, and a stronger protective effect than NAC reducing ROS production 
and the apoptosis due to the TNF and cycloheximide administration in U937 cells68. Taken together, these studies 
suggest that CeO2NPs antioxidant effects are similar to the exerted by NAC, however, given their long-time dep-
osition in the tissue and their regenerative capacity, CeO2NPs could exert a sustained antioxidant effect that may 
be more useful for chronic oxidative stress treatment.
Previous studies have shown significantly augmented ROS production by liver mitochondria in MCDD 
rodents. In particular, they exhibit excessive production of H2O269. The marked reduction of both SFAs and UFAs 
observed in our MCDD animals treated with CeO2NPs is likely due to a diminished ROS production derived 
from the antioxidant properties of these nanoparticles. This would be also consistent with previous data from 
our laboratory showing that CeO2NPs reduce oxidative stress in H2O2-stimulated human derived cancer cells 
in culture30. In addition, CeO2NPs treatment also resulted in a significant increase in docosahexaenoic acid, a 
modulator of inflammatory response which has been considered as a potential treatment for NAFLD in chil-
dren70. The current investigation provides for the first-time evidence that CeO2NPs induce changes in the hepatic 
gene expression of markers related to fatty liver and oxidative stress in the liver of MCDD fed rats, including 
Epx, Prdx4, Cpt1a, Il1β, Il10, Ccl5 (RANTES), Cd36, Lepr and Cebpb. Epx and Prdx4 are peroxidases whereas 
Cpt1a catalyzes the transfer of long chain FAs to carnitine for translocation across the mitochondrial inner mem-
brane71–73. Moreover, increased Cpt1a expression has been previously observed in MCDD rats74. Our findings 
suggest that by decreasing Cpt1a expression CeO2NPs may improve the impairment in FA β-oxidation occurring 
in NAFLD animals. On the other hand, Il1β is one of the most potent proinflammatory cytokines and Cd36 and 
Lepr are involved in adipokine signaling. Cd36 mediates the cellular uptake of very long chain fatty acids and 
is known to be upregulated under hyperlipidemic conditions, contributing to the onset of hepatic steatosis75. 
Moreover, it has been shown that hepatocyte-specific disruption of Cd36 in high-fat diet mice reduces liver CE 
and TC (the largest being oleic acid) and improves inflammatory markers76. Lepr is the receptor for leptin. Ccl5 is 
a broader activator of several chemokine receptors, including Ccr1, Ccr3, Ccr4 and Ccr5 and it has been claimed 
as an important player in the pathophysiology of NAFLD-progression77. Finally, Cebpb is an important tran-
scription factor that regulates the expression of genes involved in immune and inflammatory response which has 
been suggested to play a pivotal role in the pathogenesis of experimental NASH78. Taken together these results 
indicate that major beneficial effects of CeO2NPs are related to an anti-inflammatory effect secondary to general 
disruption of cytokine signaling.
In this study the experiments were performed using the MCDD experimental model of NAFLD. This model 
induces changes in the liver by nutritional deficiency and does not reflect the metabolic profile and the main etio-
pathogenic factors of human NAFLD79–81. However, in contrast to other NAFLD models, MCDD induces repro-
ducible histological features of human NAFLD, with significant inflammation, fibrogenesis, and a liver redox 
balance similar to human patients37,38. Therefore, MCDD model is indicated for studying the consequences of 
fat accumulation, inflammation, oxidative stress and fibrogenesis in the liver38. Also, the MCDD model show sex 
differences regarding the degrees of steatosis and hepatic lipid content being higher in male rats than in female 
rats. The mechanisms underlying these differences are uncertain82. The current study has been performed in male 
Wistar rats, therefore, further studies would be necessary to confirm that the results are reproduced in females. 
Liver and spleen are the main target organs of CeO2NPs when administered intravenously30,66,83, thus, in this 
study, CeO2NPs were administered by iv route the rats to assure a high deposition in the liver. No toxicity or seri-
ous side effects were observed due to CeO2NPs iv administration, however, given the potential therapeutic value 
Gk, Glycerol kinase; Hmgcr, 3-hydroxy-3-methylglutaryl-Coenzyme A reductase; Igf1, Insulin-like growth 
factor 1; Igfbp1, Insulin-like growth factor binding protein 1; Il1B, Interleukin 1 beta; Lepr, leptin receptor; 
Lpl, Lipoprotein lipase; Mlxipl, MLX interacting protein-like; Nr1h4, Nuclear receptor subfamily 1, group 
H, member 4; Pck2, Phosphoenolpyruvate carboxykinase 2 (mitochondrial); Pdk4, Pyruvate dehydrogenase 
kinase, isozyme 4; Pklr, Pyruvate kinase, liver and RBC; Ppard, Peroxisome proliferator-activated receptor delta; 
Ppargc1a, Peroxisome proliferator-activated receptor gamma, coactivator 1 alpha; Scd1, Stearoyl-Coenzyme 
A desaturase 1; Serpine1, Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), 
member 1; Slc27a5, Solute carrier family 27 (fatty acid transporter), member 5; Slc2a1, Solute carrier family 
2 (facilitated glucose transporter), member 1; Slc2a4, Solute carrier family 2 (facilitated glucose transporter), 
member 4; Socs3, Suppressor of cytokine signaling 3; Srebf1, Sterol regulatory element binding transcription 
factor 1; Srebf2, Sterol regulatory element binding transcription factor 2; Tnf, Tumor necrosis factor (TNF 
superfamily, member 2). *p < 0.05, **p < 0.01, ***p < 0.001 vs. control rats. †p < 0.05 vs. MCDD rats receiving 
vehicle. Unpaired Student’s t-test.
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of CeO2NPs in NAFLD it would be interesting to explore less invasive routes of administration. In this respect, 
some studies indicate that oral administration of CeO2NPs show higher excretion of the nanoceria and less accu-
mulative nanodeposition than intravenous and intraperitoneal administration66,83. Even so, liver remains as the 
main target for CeO2NPs deposition after oral administration84. Furthermore, anti-inflammatory properties of 
CeO2NPs have been proved when administered intragastrically, preventing and liver injury in an obesity experi-
mental model33. Still, further studies are required to enhance nanoceria administration options.
In conclusion, the results of the current investigation show that in the MCDD experimental model of NAFLD 
characterized by malnutrition, weight loss, reduced serum levels of triglycerides and cholesterol, activation of 
liver tissue proinflammatory pathways, enhanced liver concentration of FAs and significant overexpression of 
genes related to fatty liver and ROS metabolism, the administration of CeO2NPs reduced the size and content 
of hepatocyte lipid droplets, the hepatic concentration of TG-derived MUFA, CE-derived SFA and UFA and 
messenger expression of several genes involved in cytokine, adipokine and chemokine signaling pathways. These 
findings, therefore, suggest that CeO2NPs could be of beneficial value in NALFD.
Methods
Synthesis and characterization of CeO2NPs. 4 nm CeO2NPs were synthesized by the chemical precip-
itation of cerium (III) nitrate hexahydrated (Sigma-Aldrich, St. Louis, MO, USA) in a basic aqueous solution24. 
Briefly, 10 mM of cerium (III) nitrate hexahydrate was dissolved in 100 ml of milliQ H2O at RT. The solution was 
left for 30 minutes under stirring. 1 mL of TMAOH 1.0 (0.02 M in H2O) was added to the 100 mL solution at a 
final concentration of 10 mM, then, the mixture was left under stirring for 24 hours. Afterwards, the CeO2NPs 
were centrifugated and resuspended in 1 mM TMAOH aqueous solution, which act as a stabilizer. CeO2NPs were 
kept at 4 °C until the administration to animals. The surface charge of the CeO2NPs was analyzed in a Z-sizer 
(Malvern, Worcestershire, UK) while the size was evaluated by high-resolution (HR-TEM) in the Tecnai G2 F20 
at 200 kV (FEI, Oregon, USA). The crystal structure was analyzed by HR-TEM (Tecnai 200 kV) and XRD (Xpert 
Pannalytical, MA, USA), and the light interaction by UV-VIS spectroscopy (Shimatzu, Kyoto, Japan). The size 
distribution was analyzed by Image J (National Institutes of Health, Bethesda, MD, USA).
Animal procedures and dietary induction of liver steatosis in rats. The studies were performed in 
20 male adult Wistar rats (Charles-River, Saint Aubin les Elseuf, France). Fifteen rats were fed with methionine 
and choline deficient diet (MCDD, TD 90262, Harlan Teklad). Five control rats were fed ad libitum with standard 
chow (Teklad global 14% protein rodent maintenance diet, Envigo). After 6 weeks of MCDD, rats were eutha-
nized by isofluorane overdose. Livers obtained from each animal were immediately frozen in dry ice and stored 
at −80 °C for further analysis or fixed in 10% buffered formalin for hematoxylin and eosin (H&E) and immunos-
taining analysis. Serum samples were also obtained and kept at −20 °C until further analysis.
Figure 6. A volcano plot showing of the differentially expressed genes related to fatty liver in a pair-wise 
comparison of vehicle- and CeO2NP-treated MCDD rats. Significance was set at a p value based on a Student’s 
t-test of 0.05 [−log10 (p-value) ≥ 1.30]. The biological cut-off was set at a fold regulation of ±2 fold [−1 ≥ log2 
(FC of CeO2NPs/Vehicle) ≥ 1]. The top 15 differentially expressed genes are labeled with their corresponding 
gene ID. The different color codes used represent biologically but not statistically significant genes (grey) and 
both biologically and statistically significant down-regulated (green) genes in CeO2NP treated rats.
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Genes
MCDD rats
Vehicle (n = 7) CeO2NPs (n = 7)
Antioxidants:
Cat −2.86*** −2.92***
Ehd2 3.12** 2.41*
Epx 2.30* −1.03††
Gpx1 −1.85** −2.40***
Gpx2 68.00** 45.09**
Gpx3 12.53** 8.92**
Gpx7 8.16** 5.30***,†
Gstp1 3.63** 2.29**,†
Mpo −7.82 −9.60
Prdx2 2.05** 1.46*,†
Prdx4 1.23 −4.13†
Ptgs1 3.03* 2.07**
Ptgs2 4.99* 3.51
Serpinb1b 11.73* 6.64
Srxn1 4.42** 3.07**
Vimp 2.85** 1.78**,†
Reactive Oxygen Species (ROS) Metabolism:
Aox1 −1.94** −3.52***,†
Ccl5 2.28* 1.10†
Cyba 6.57** 4.57**
Fmo2 2.93* 1.82
Gclm 1.22 −3.62
Hmox1 4.09** 2.65***,†
Krt1 2.27 1.72
Ncf1 5.19** 3.41**,†
Ncf2 5.25** 3.61*
Nos2 2,74* 2.75
Nox4 −2.64** −2.01*
Nqo1 4.00 4.22*
Prnp 3.99* 2.55*
Scd1 −35.60*** −21.55***
Tpo 2.65 −1.20
Txnrd1 3.46 1.18
Ucp2 3.80** 2.79*
Oxygen Transporters:
Cygb 3.29** 2.55
Dnm2 2.26* 1.53*
Hba1 −4.21** −3.21*
Slc38a1 6.06** 3.62*
Vim 5.05** 4.30*
ER stress
Atf3 27.35** 18.23*
Ddit3 2.76* 1.94**
Table 8. Messenger expression of genes involved in oxidative stress and antioxidant defense showing 2-fold or 
greater regulation in liver between controls and MCDD rats treated with vehicle or CeO2NPs. Aox, Aldehyde 
oxidase 1; Atf3, Activating transcription factor 3; Cat, Catalase; Ccl5, C-C motif chemokine ligand 5; Cyba, 
Cytochrome b-245, alpha polypeptide; Cygb, Cytoglobin; Ddit3, DNA Damage Inducible Transcript 3; 
Dnm2, Dynamin 2; Ehd2, EH Domain Containing 2; Epx, Eosinophil Peroxidase; Fmo2, Flavin Containing 
Monooxygenase 2; Gclm, Glutamate cysteine ligase, modifier subunit; Gpx1, Glutathione peroxidase 1; Gpx2, 
Glutathione peroxidase 2; Gpx3, Glutathione peroxidase 3; Gpx7, Glutathione peroxidase 7; Gstp1, Glutathione 
S-transferase pi 1; Hba1, Hemoglobin alpha 1; Hmox1, Heme oxygenase (decycling) 1; Krt1, Keratin 1; 
Mpo, Myeloperoxidase; Ncf1, Neutrophil cytosolic factor 1; Ncf2, Neutrophil cytosolic factor 2; Nos2, Nitric 
oxide synthase 2, inducible; Nox4, NADPH oxidase 4; Nqo1, NAD(P)H dehydrogenase, quinone 1; Prdx2, 
Peroxiredoxin 2; Prdx4, Peroxiredoxin 4; Prnp, Prion protein; Ptgs1, Prostaglandin-endoperoxide synthase 1; 
Ptgs2, Prostaglandin-endoperoxide synthase 2; Scd1, Stearoyl-Coenzyme A desaturase 1; Serpinb1b, Serine 
(or cysteine) peptidase inhibitor, clade B, member 1b; Slc38a1, Solute carrier family 38, member 1; Srxn1, 
Sulfiredoxin 1 homolog; Tpo, Thyroid Peroxidase; Txnrd1, Thioredoxin Reductase 1; Ucp2, Uncoupling protein 2 
(mitochondrial, proton carrier); Vim, Vimentin; Vimp, VCP-interacting membrane protein. *p < 0.05, **p < 0.01, 
***p < 0.001 vs. control rats; †p < 0.05, ††p < 0.01 vs. MCDD rats receiving vehicle. Unpaired Student’s t-test.
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ceo2NPs administration in MCDD rats. CeO2NPs or vehicle were diluted in saline solution and given 
as a bolus (500 µl) through the tail vein. CeO2NPs (0.1 mg/kg bw) or vehicle (saline solution containing 0.8 mM 
TMAOH ammonium salts) were injected twice a week for 2 consecutive weeks starting at the third week after 
liver steatosis induction.
Morphometric measurement of steatosis and fibrosis. Liver sections (4 µm) were stained with H&E 
and digital images were obtained at a magnification of 100x with a microscope (Eclipse E600; Nikon, Tokio, 
Japan) and a digital camera (RT-Slider Spot; Diagnostic Instruments, Sterling Heights, MI, USA). For all the 
cases, the settings of the digital camera, microscope and software were the same. Ten digital images were taken 
for each slide. Image segmentation was made by selecting a few distinct fat droplets serving as reference. Area 
and roundness (R) were measured for each object. The formula (4 × π × area/perimeter2) was used to calculate 
R, which is equal to 1 for perfectly round objects and decreases toward 0 for more irregular objects. Filters were 
set to exclude exceedingly large objects (~3800 µm2) and objects with low roundness (R ≤ 0.35), which typically 
represented sinusoidal and vasuclar spaces or optically clear artifacts instead of fat droplets. All the indentified 
objects were manually inspected to ensure the quality. Fat content was defined as the percentage of total surface 
area occupied by fat droplets. The results were analyzed using imaging software (ImageJ, National Institutes of 
Health, Bethesda, MD, USA).
Fibrosis measurement was performed as described previously85. Briefly, using 0.1% Sirius red F3B (Sigma 
Aldrich, St. Louis, MO, USA) in saturated picric acid (Sigma-Aldrich, St. Louis, MO, USA). The relative fibrosis 
Figure 7. A volcano plot showing the differentially expressed genes related to oxidative stress in a pair-wise 
comparison of vehicle- and CeO2NP-treated MCDD rats. Significances was set at a p value based on a Student’s 
t-test of 0.05 [−log10 (p-value) ≥ 1.30]. The biological cut-off was set at a fold regulation of ±2 fold [−1 ≥ log2 
(FC of CeO2NPs/Vehicle) ≥ 1]. The top 6 differentially expressed genes are labeled with their corresponding 
gene ID. The different color codes used represent biologically but not statistically significant genes (grey) and 
both biologically and statistically significant down-regulated (green) genes, in CeO2NP treated rats.
Figure 8. Effect of CeO2NPs on the expression of adipokine signaling, fatty acid oxidation and inflammation 
response-related genes in MCDD rats. The messenger RNA expression of Cd36, Lepr, Cebpb, Ccl5 and Il1β was 
assessed by real-time PCR in liver tissue of MCDD rats treated with vehicle or CeO2NPs. Unpaired Student’s 
t-test. Results are given as mean + SEM.
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area was assessed by analyzing 32 fields of Sirius red-stained liver sections per animal. Each field was acquired 
as described above and the results were analyzed using imaging software (ImageJ, National Institutes of Health, 
Bethesda, MD, USA). To evaluate the relative fibrosis area, the collagen area measured was divided by the net field 
area and then multiplied by 100. Subtraction of the vascular luminal area from the total field area yielded the final 
calculation of the net fibrosis area. The amount of fibrosis measured in each animal was analyzed, and the average 
value was presented as a percentage85.
Immunodetection of CD68. Liver sections from fibrotic rats underwent microwave antigen retrieval to 
unmask antigens hidden by cross-linkage occurring during tissue fixation. Endogenous peroxidase activity was 
blocked by hydrogen peroxide pretreatment for 10 min and with 5% goat serum for 45 min. The sections were 
then stained with mouse anti-CD68 (1:150; AbD Serotec, Oxford, UK, RRID:AB_2291300) and incubated for 
1.5 h at RT. For antigen detection, the LSAB 2 System-HRP (Dako Denmark A/S) was used, and antigen visual-
ization was achieved with streptavidin peroxidase and counterstained with hematoxylin. Immunostaining was 
performed without the first antibody for the negative controls. Macrophages (CD68-positive cells) in the middle 
and margin of the septa were assessed by counting 20 random fields per each section. The mean cell count for 
each sample was calculated85.
Total concentration of malondialdehyde (MDA) in liver tissue. MDA concentration in the liver 
of control and MCDD rats non-treated (Vehicle) or treated with CeO2NPs were measured with the Lipid 
Peroxidation (MDA) Assay Kit (Abcam, Cambridge, United Kingdom) by following the manufacturer’s instruc-
tions. Briefly, liver homogenates were prepared using lysis solution and a Dounce homogenizer. The samples and 
the MDA standards were mixed with TBA solution and incubated at 95 °C for 1 hour. After a 10 minutes incu-
bation on ice the samples and standard were read spectrophotometrically at 532 nm. The MDA concentration in 
the samples was determined by comparison with the MDA standard curve and presented as MDA nmol/mg of 
liver tissue.
Hepatic lipid profiling by mass spectrometry analysis. Liver tissue (50 mg) was homogenized 
in chloroform: methanol (2:1, v/v, Scharlab, Barcelona, Spain, 372978 and PanReact AppliChem, Darmstadt, 
Germany, 1310911611, respectively) containing 0.005% butylated hydroxytoluene (Sigma Aldrich, Saint 
Louis, USA, W218405). Glyceryl trinonadecanoate (TG (19:0/19:0/19:0) Sigma Aldrich, Madrid, Spain), cho-
lesteryl heptadecanoate (CE (17:0)), 1,2-dinonadecanoyl-sn-glycero-3-phosphocholine (PC (19:0/19:0)) and 
1,2-dipentadecanoyl-sn-glycero-3-phosphoethanolamine (PE (15:0/15:0)) were used as internal standards. 
Separation of triglycerides (TG), cholesterol esters (CE), phosphatidylcholines (PC) and phosphatidylethanola-
mines (PE) from total lipid liver extracts dissolved in chloroform was performed by solid-phase extraction (SPE) 
using aminopropyl silica columns as described previously86,87. First, the CE and TG fractions were eluted with 
chloroform. Thereafter, PC were eluted with chloroform: methanol (3:2, v/v), and finally, PE were eluted with 
methanol. In order to isolate CE and TG, the first fraction was evaporated under nitrogen stream, dissolved in 
hexane (Merck Millipore, Darmstadt, Germany, 104374) and transferred to a fresh preconditioned aminopropyl 
silica column preconditioned with hexane. Then CE were eluted with hexane, and TG were eluted with hexane: 
chloroform: ethylacetate (100:5:5, v/v).
All solvent fractions containing isolated lipids were dried under nitrogen stream and transesterified (FAME) 
with 0.5 M NAOH and boron trifluoride (Sigma Aldrich, Saint Louis, USA, B1252) in methanol. GC–MS anal-
yses of FAME were performed on a Shimadzu GCMS QP2010 Ultra instrument (Kyoto, Japan) as previously 
described88. Briefly, final extracts were injected in spitless mode (valve opened at 1 min) into the gas chromato-
graph interfaced with a mass selective detector. Chromatographic separation was achieved on a Sapines-5MS+ 
capillary column (30 m × 0.25 mm internal diameter × 0.25 μm film thickness) from Teknokroma (Barcelona, 
Spain) with helium as a carrier gas at a constant velocity of 50 cm/s. The temperature program was set to begin 
at 50 °C, maintained at this temperature for 3 min, elevated at 80 °C min−1 to 240 °C, then increased at 2 °C min−1 
until 290 °C and finally maintained for 2 min at 290 °C. The ion source and transfer line temperatures were set 
at 250 °C and 280 °C, respectively. The mass detector was operated in scan mode. Identification of the FAME in 
the sample extracts was achieved by mass spectrum and GC retention time comparison with reference standards 
(Sigma). Results are expressed as nmol of FA/mg liver tissue.
Oxidative stress and fatty liver gene expression PCR array in the liver of MCDD rats. Total RNA 
was extracted using an RNA extraction column kit (RNAeasy, Qiagen, Venlo, The Netherlands). To remove resid-
ual DNA, RNA preparations were treated with RNase-Free DNAse set (Qiagen). First strand cDNA was synthe-
sized from 500 ng total of RNA using an RT2 first-strand kit (Qiagen), and PCR arrays were performed according 
to the manufacturer’s protocols (SABiosciences, Frederick, MD). Real-time PCR arrays were performed using 
the rat Oxidative Stress RT2 ProfilerTM PCR array, (SABiosciences) and the rat Fatty Liver RT2 Profiler PCR array 
according to the manufacturer’s protocol. These PCR arrays combine the quantitative performance of SYBR 
Green-based real-time PCR with the multiple gene profiling capabilities of microarrays to profile the expression 
of 86 key genes involved in oxidative stress or NAFLD. PCR array plates were processed in a Light Cycler 480 
(Roche Diagnostics) using automated baseline and threshold cycle detection. Normalization of gene expression 
was performed using internal controls to determine the fold change in gene expression between the test and 
the control samples. The relative quantity of product was expressed as fold-induction of the target gene com-
pared with the reference gene according to the formula 2−ΔΔCT. Data were interpreted using the SABiosciences 
web-based PCR array data analysis tool (http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php).
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RT-PCR validation. To confirm the effect induced by CeO2NPs on gene expression unveiled by the 
RT2 profiler we used RT-PCR. As described previously89, total RNA was extracted from the middle liver lobe 
of control and fibrotic rats using a commercially available kit (RNAeasy; QIAGEN, Hilden, Germany). The 
RNA concentration was determined by spectrophotometric analysis (ND-100 spectrophotometer; Thermo 
Fischer Scientific, Waltham, MA, USA). One microgram of total RNA was reverse-transcribed using a cDNA 
synthesis kit (High-Capacity cDNA Reverse Transcription Kit; Applied Biosystems, Foster City, CA, USA). 
The specific primers and probes used for the different genes studied were designed to include intron span-
ning using the Universal Prove Library Assay Design Center through ProbeFinder version 2.5 software 
(Roche Diagnostics, Indianapolis, IN, USA; http://lifescience.roche.com/shop/es/mx/overviews/brand/
universal-probe-library). The panel included the following: CCAAT/Enhancer Binding Protein Beta (Cebpb) 
(probe 70: left 5′-CTTCAGCCCCTACCTGGAG-3′ and right 5′-GAGGTCGGAAAGGAAGTCGT-3′); inter-
leukin 1 Beta (Il1β) (probe 76: left 5′-CAGGAAGGCAGTGTCACTCA-3′ and right 5′-TCCCACGAGTCAC 
AGAGGA-3′); cluster of differentiation 36 (Cd36) (probe 75: left 5′-GCGACATGATTAATGGCACA-3′ 
and right 5′-TGGACCTGCAAATGTCAGAG-3′); leptin receptor (Lepr) (probe 66: left 5′-AAAGC 
ACCATTTCCACTTCAA-3′ and right 5′-GCAGAGATGTATCCGAGACGA-3′) and C-C Motif Chemokine 
Ligand 5 (Ccl5) (probe 16: left 5′-CTCACCGTCATCCTCGTTG-3′ and right 5′-GAGTGGTCTCCG 
AGCCATA-3′). Hypoxanthine-guanine phosphoribosyltransferase (Hprt) (probe 95: right 5′-GACCGG 
TTCTGTCATGTCG-3′ and left 5′-ACCTGGTTCATCATCACTAATCAC-3′) was used as the reference 
gene. Primers were designed according to rat sequences (GenBank codes NM_001301715.1, NM_031512.2, 
NM_031561.2, NM_012596.1, NM_031116.3 and NM_012583.2). Real-time quantitative polymerase chain reac-
tion was analyzed in duplicate and performed with the LightCycler 480 (Roche Diagnostics). A 10-µl volume 
reaction of diluted 1:8 cDNA, 200 nM primer dilution, 100 nM prevalidated 9-mer probe (Universal ProbeLibrary) 
and FastStart TaqMan Probe Master (Roche Diagnostics) were used in each PCR. A fluorescence signal was cap-
tured during each of the 45 cycles (denaturizing for 10 s at 95 °C, annealing for 20 s at 60 °C, and extension for 1 s at 
72 °C). Water was used as a negative control. Relative quantification was calculated using the comparative thresh-
old cycle (Ct), which is inversely related to the abundance of mRNA transcripts in the initial sample. The mean Ct 
of duplicate measurements was used to calculate ΔCt as the difference in Ct for target and reference. The relative 
quantity of product was expressed as fold induction of the target gene compared with the reference gene according 
to the formula 2−ΔΔCT, where ΔΔCt represents ΔCt values normalized with the mean ΔCt of control samples.
Measurements and statistical analysis. Biochemical standard parameters of liver function were meas-
ured in the BS-200E Chemistry Analyzer (Mindray Medical International Ltd, Shenzhen, China). Quantitative 
data were analyzed using GraphPad Prism 5 (GraphPad Software Inc., San Diego, CA), and statistical analy-
sis of the results was performed by unpaired Student’s t test, one-way analysis of variance (ANOVA),The 
Newman-Keuls post hoc test and the Kruskal-Wallis test with the Dunn post hoc test when appropriate. Unpaired 
Student’s t-test was also performed when appropriate. Results are expressed as mean ± standard error of the mean 
(SEM) and considered significant p ≤ 0.05.
Ethical approval. The experimental protocol was approved by the Investigation and Ethics Commitee of the 
Hospital Clínic Universitari. All applicable international, national and institutional guidelines for the care and use 
of animals were followed, and the study was performed according to the ethical standards of the Investigation and 
Ethics Committee of the Hospital Clinic Universitari.
Compliance with ethical standards. All applicable international, national, and/or institutional guide-
lines for the care and use of animals were followed. All procedures performed in studies involving animals were 
approved by the Investigation and Ethics Committee of the Hospital Clinic Universitari, and all the experiments 
were performed in accordance with their ethical standards.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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